The marketing authorization application for ADCETRIS in relapsed or refractory Hodgkin lymphoma and systemic ALCL, filed by Takeda Global Research & Development Centre (Europe), was accepted by the European Medicines Agency in June 2011.

Recently, it has been demonstrated that 25% to 60% of ALCL lymphomas carry the t(2;5)(p23;q35) translocation, (3) which results in the formation of a novel chimeric protein, nucleophosmin/anaplastic lymphoma kinase (ALK), believed to be involved in neoplastic transformation.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.